Cargando…

Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report

BACKGROUND: After the failure of second-line standard therapy, effective treatment options for metastatic colorectal cancer are limited, and the duration of remission cannot meet clinical needs. In addition, associated drug toxicity may lead to treatment interruption that may affect patient outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qu, Fan-Jie, Wu, Shuang, Kong, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237021/ https://www.ncbi.nlm.nih.gov/pubmed/37275454 http://dx.doi.org/10.4251/wjgo.v15.i5.902

Ejemplares similares

Tegafur/gimeracil/oteracil‐induced eosinophilic pneumonia
por: Sumi, Toshiyuki, et al.
Publicado: (2020)

Activity and Safety of Tegafur, Gimeracil, and Oteracil Potassium for Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis
por: Zhang, Ximing, et al.
Publicado: (2021)

Short-term clinical effect of conformal radiotherapy combined with tegafur gimeracil oteracil potassium in treating recurrent esophagus cancer
por: Jiao, Yuyan, et al.
Publicado: (2016)

Successful management of therapy‐related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil
por: Nakako, Soichiro, et al.
Publicado: (2021)

A fatal myelosuppression, diarrhea and neurotoxicity induced by combination of irinotecan and tegafur-gimeracil-oteracil potassium in the treatment of colon cancer: a case report
por: Liu, Yang-Xi, et al.
Publicado: (2020)

Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma
por: Wang, Zhenfeng, et al.
Publicado: (2022)

Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial
por: Zhang, Wen, et al.
Publicado: (2021)

Safety of alternate-day treatment with TS-1(TM) (tegafur/gimeracil/oteracil) in tumor-bearing dogs: a pilot study
por: NISHIYAMA, Yuta, et al.
Publicado: (2021)

Huaier Granule Combined with Tegafur Gimeracil Oteracil Potassium Promotes Stage IIb Gastric Cancer Prognosis and Induces Gastric Cancer Cell Apoptosis by Regulating Livin
por: Qi, Jing, et al.
Publicado: (2020)

Application of Evidence-Based Nursing Intervention in the Treatment of Advanced Squamous Cell Carcinoma of the Lung by Erlotinib Combined with Tegafur, Gimeracil, and Oteracil Potassium and Its Influence on Quality of Life
por: Liu, Shan, et al.
Publicado: (2021)

Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1)
por: Luo, Dongcheng, et al.
Publicado: (2022)

Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies
por: Kobayakawa, Masao, et al.
Publicado: (2011)

Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial
por: Wang, Juan, et al.
Publicado: (2020)

Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis
por: Yen, Chih-Chieh, et al.
Publicado: (2021)

Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
por: Lavacchi, Daniele, et al.
Publicado: (2023)

The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer
por: Song, Yan, et al.
Publicado: (2021)

Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial
por: Yin, Yuping, et al.
Publicado: (2022)

Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer
por: Liu, Shuai, et al.
Publicado: (2022)

Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells in vitro and in vivo
por: Harada, Koji, et al.
Publicado: (2017)

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
por: Peng, Zhi, et al.
Publicado: (2020)

Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer
por: Shu, Yefei, et al.
Publicado: (2021)

Oral Anlotinib Maintenance Therapy for an Advanced Malignant Peritoneal Mesothelioma Diagnosed by Laparoscopy After Initial Misdiagnosis to Obtain Longer Progression-Free Survival: Case Report and Literature Review
por: Qu, Fan-Jie, et al.
Publicado: (2023)

Oral Tegafur/folinic acid chemotherapy decreases phenytoin efficacy
por: Veldhorst-Janssen, N M L, et al.
Publicado: (2004)

Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer
por: Alliot, C
Publicado: (2004)

Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial
por: Hasegawa, Kiyoshi, et al.
Publicado: (2016)

Fruquintinib for refractory colorectal cancer in a pre-treated 82-year-old patient achieved a progression-free survival of 25 months: a case report
por: Wang, Yi, et al.
Publicado: (2022)

Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review
por: Xu, Xiaojing, et al.
Publicado: (2022)

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer
por: Li, Qingli, et al.
Publicado: (2022)

Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer
por: Nukatsuka, Mamoru, et al.
Publicado: (2023)

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
por: Ward, S E, et al.
Publicado: (2006)

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
por: Almond, J, et al.
Publicado: (2007)

Tegafur-induced acral hyperpigmentation
por: Teixeira, Vera, et al.
Publicado: (2011)

Reply: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer
por: Ohwada, S, et al.
Publicado: (2004)

PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report
por: Zhang, Hong-Qiang, et al.
Publicado: (2022)

Acute aortic dissection caused by fruquintinib for metastatic colorectal cancer—a case report and literature review
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Reply: The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
por: Ward, S E
Publicado: (2007)

Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study.
por: Palmeri, S., et al.
Publicado: (1990)

Low expression of MUC2 is associated with longer disease-free survival in patients with colorectal carcinoma
por: Al-Maghrabi, Jaudah, et al.
Publicado: (2019)

Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report
por: Lin, Sen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_anj100ir09ekonqbo6ua59b2e7